Myriad Genetics prodá Labcorp své podnikání v oblasti prenatálního testování za 210 milionů USD v hotovosti a k tomu hodnotu zásob; dokončení transakce se očekává na začátku roku 2027.
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.
“This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution and driving shareholder value,” said Sam Raha, President and CEO, Myriad Genetics. “This transaction is expected to be accretive to Myriad’s revenue growth and profitability, while meaningfully strengthening the balance sheet to support continued investment in our strategic priorities tied to the cancer care continuum and long-term value creation. Working closely with Labcorp, one of the nation’s largest laboratory service providers, we expect a smooth transition that preserves uninterrupted patient access to our prenatal tests.”
When complete, the transaction is expected to provide more patients and physicians with expanded access to Labcorp’s comprehensive, high-quality laboratory services, convenient patient service center network, robust data analytics and digital tools.
"This transaction supports Labcorp's specialty testing growth strategy," said Bryan Vaughn, Executive Vice President and President of Diagnostics, Labcorp. “Myriad Genetics has built a highly complementary reproductive genetics platform, supported by innovative screening solutions and deep scientific expertise. By combining these capabilities with Labcorp's operational strength and high-quality women's health portfolio, we aim to improve outcomes, expand access to advanced screening solutions and enhance the patient and provider experience.”
Labcorp expects the transaction to add approximately $160 million in revenue in year one, to be slightly accretive to adjusted earnings in year one, and to reach average diagnostics segment margins by end of year two, once fully integrated.
Over the last twelve months, Myriad’s Prenatal Health testing portfolio has been used by thousands of providers and over 600,000 patients. Myriad plans to provide further commentary regarding this transaction, and other related organizational changes, on its third quarter earnings call on November 4, 2026.
The deal is subject to regulatory clearance and customary closing conditions, and the transaction is expected to close by early 2027.
Guggenheim Securities, LLC is acting as exclusive financial advisor, and Covington & Burlington LLP is acting as legal advisor to Myriad Genetics.
Barclays is acting as financial advisor, and Polsinelli is acting as legal advisor to Labcorp.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the sale of Myriad’s Prenatal Health testing business; the expected benefits of the transaction, including that it will be accretive to Myriad’s revenue growth and profitability, strengthen its balance sheet, and support investment in its strategic priorities; and the expectation that the transaction will close by early 2027. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the Myriad’s filings with the U.S. Securities and Exchange Commission, including Myriad’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in Myriad’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
This press release contains forward-looking statements, including, but not limited to, statements with respect to the anticipated benefits of the transaction for providers and patients, its advancement of Labcorp’s strategic priorities, and the expected financial impact of the transaction, including expected post-closing revenues and margins, and the timing of achieving such financial results.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond Labcorp's control. These factors, in some cases, have affected and in the future (together with other factors) could affect Labcorp's ability to implement its business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
Labcorp has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in Labcorp's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in subsequent quarterly reports on Form 10-Q and its other filings with the SEC. The information in this press release should be read in conjunction with a review of Labcorp's filings with the SEC including the information in its most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
Labcorp koupí od OPKO Health vybraná aktiva BioReference Health za 722 milionů USD v hotovosti při uzavření transakce, s případnou úpravou podle tržeb při uzavření a možným podmíněným doplatkem až 150 milionů USD na základě tržeb z testu 4Kscore.
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, LLC, a wholly owned subsidiary of OPKO Health.
OPKO
Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections and certain operational assets, including over 80 additional patient service centers. As part of the agreement, Labcorp will also acquire BioReference Health's proprietary 4Kscore® Test, an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision, making this important test more broadly available to patients across the country.
When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, including a broad specialty testing menu, convenient patient service center network and robust data analytics and digital tools.
"This acquisition strengthens our ability to deliver affordable, high-quality, specialized diagnostic services to more patients and providers around the country," said Bryan Vaughn, Executive Vice President and President of Diagnostics at Labcorp. "By expanding our clinical, women's health, urology and corrections testing capabilities and broadening access to innovative diagnostics such as the FDA-approved 4Kscore Test, we can help providers make more informed decisions, improve patient care and increase access to the comprehensive laboratory services people need to live healthier lives."
"This transaction will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business," said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. "Labcorp's national scale and capabilities will broaden patient and provider access to BioReference's 4Kscore Test to many more patients across the country. We believe this transaction is an important catalyst to further unlock additional value for our shareholders."
The purchase price for the transaction is $722 million in cash at closing, subject to an upward or downward adjustment (if any) based on closing business revenues, and up to an additional $150 million in an earnout based on revenue from the 4Kscore Test. Labcorp expects the business revenue to be approximately $250 million in the first year after close, based on Labcorp's current post-closing forecasts.
This transaction is subject to regulatory approvals and customary closing conditions. Until the transaction closes, there will be no changes to operations or services, and both companies will continue to operate independently.
Lazard is serving as Labcorp's financial advisor, Hogan Lovells Cadwalader US LLP is serving as lead transaction counsel and Parker Poe is serving as real estate counsel.
Piper Sandler & Co. is serving as OPKO's exclusive financial advisor, and Greenberg Traurig P.A. is serving as legal counsel.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
About OPKO
OPKO Health, Inc. (Nasdaq: OPK) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to (a) the anticipated impact of the transaction including expanding access to comprehensive, high-quality laboratory services, (b) increased access to testing services and expanded testing capabilities including with respect to the 4Kscore Test, (c) anticipated timing to closing, final purchase price, post-closing revenue, and earnout for the 4Kscore Test, (d) other anticipated potential benefits of the acquisition to Labcorp and OPKO Health, and (e) required regulatory approvals and customary closing conditions.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the control of Labcorp or OPKO Health. These factors, in some cases, have affected and in the future (together with other factors) could affect the ability of Labcorp or OKPO Health to implement its respective business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
Neither Labcorp nor OPKO Health has any obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in each of Labcorp's and OPKO Health's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the headings RISK FACTORS and MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, and in each of Labcorp's and OPKO Health's other filings with the SEC.
Labcorp ve spolupráci se společností Thrive Global spustil test Thrive 5 Health Test, který hodnotí pět ukazatelů kardiometabolického zdraví a nabízí doporučení pro každodenní návyky.
First lab test offered in collaboration with Thrive Global Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habits Delivers insights from five key cardiometabolic health indicators paired with educational content and recommended Thrive Microsteps® , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Thrive 5 Health Test, the first lab test offered in collaboration with Arianna Huffington's behavior change technology company, Thrive Global. Available through Labcorp OnDemand, the offering pairs trusted health insights from Labcorp with Thrive Global's behavior change approach, giving consumers a better understanding of their health and practical ways to improve it.
"Too often, we get information about our health without guidance on what to do about it," said Arianna Huffington, founder and CEO of Thrive Global. "Through our collaboration with Labcorp, we are closing that gap by combining Thrive Global's behavior change approach with lab testing for the first time. Labcorp's scientific expertise helps people better understand what's happening inside their bodies, and Thrive Global then helps turn that understanding into small daily habits that improve health—whether they're managing a chronic condition or taking steps to protect their health for the future."
From Health Insights to Action
The Thrive 5 Health Test delivers insights from five cardiovascular, inflammatory and metabolic health indicators: ApoB for cholesterol-related cardiovascular risk, hs-CRP for inflammation, HbA1c for blood sugar, blood pressure and body mass index. Together, the five measures provide a more complete view of an individual's cardiometabolic health than any single measure alone and help identify areas where focused action may have a meaningful impact.
After receiving their results, consumers gain access to educational content from Thrive Global and recommended Thrive Microsteps®: small daily actions related to food, movement, sleep, stress management and connection that support sustainable behavior change. By combining health insights with actionable next steps, the Thrive 5 Health Test helps consumers better understand their cardiometabolic health and make meaningful changes to improve it.
"Arianna Huffington and Thrive Global have spent years helping people understand that better health is shaped not only by what we know, but by what we do every day," said Amy Summy, executive vice president and chief marketing officer at Labcorp. "By combining Labcorp's scientific expertise and nationwide network with Thrive Global's leadership in behavior change, we can help people move from knowing their numbers to understanding what they can do about them. That's a fundamentally more useful health experience for consumers."
Convenient Testing, Meaningful Insights
Consumers can purchase the Thrive 5 Health Test through Labcorp OnDemand and schedule testing at select Labcorp patient service centers nationwide. Results, educational content and recommended Thrive Microsteps are delivered through Labcorp's secure patient portal and MyLabcorp™ mobile app.1 Consumers can use this information to consult with their healthcare provider and determine whether additional follow-up is appropriate.
The Thrive 5 Health Test reflects Labcorp's commitment to creating new consumer health experiences that bring trusted scientific insights directly to individuals and help them take a more active role in improving their health.
To learn more or purchase the Thrive 5 Health Test, visit https://www.ondemand.labcorp.com/lab-tests/thrive-five-health-test.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
1All resources within this program are designed for general wellbeing support and are intended for informational purposes only. They do not constitute medical advice, clinical recommendations, or a substitute for the guidance of a qualified healthcare provider. Always consult your healthcare provider about guidelines that are right for you.
Labcorp rozšiřuje specializaci v onkologii, ženském zdraví, autoimunitních onemocněních a neurologii, což podpořilo růst tržeb. Zároveň zvyšuje marže díky AI a automatizaci.
Key Takeaways Labcorp is expanding specialty testing in oncology, women's health, autoimmune disease and neurology.Labcorp's acquisitions and partnerships added to revenue growth and expanded access to specialty testing.Labcorp uses AI, automation and efficiency efforts to lift margins despite cost and reimbursement risks. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is expanding in high-growth specialty testing markets while broadening its consumer testing business. Acquisitions, health-system relationships and new contracts are boosting the company’s reach and supporting growth. The company also continues to leverage artificial intelligence (AI), automation and operational initiatives to strengthen productivity and margins. Meanwhile, macroeconomic uncertainty and changing reimbursement policies could pressure Labcorp’s testing volumes, costs and cash flow.
Year to date, this Zacks Rank #3 (Hold) stock has risen 23.4% compared with the 4.8% growth of the industry and a 12.7% rise of the S&P 500 composite.
The renowned healthcare diagnostics company has a market capitalization of $25.11 billion. Labcorp’s earnings yield of 5.9% favorably compares with the industry’s 3.7% yield. In the trailing four quarters, the company delivered an average earnings surprise of 3.1%.
Let’s delve deeper.
Tailwinds for LabcorpTargeted Development in High-Growth Areas: Labcorp continues to expand in specialty testing areas such as oncology, women’s health, autoimmune disease and neurology. These areas delivered double-digit revenue growth during the first half of 2026 and helped the company win new health-system and provider customers. In oncology, Labcorp launched ColoSense nationwide, expanded companion diagnostic access for prostate cancer and added an advanced DPYD genotyping test. It also entered into a clinical trial collaboration to evaluate Plasma Detect Genome MRD in patients at risk of early-stage lung cancer recurrence. The consumer business maintained double-digit growth, supported by Labcorp OnDemand, Marker by Labcorp and new at-home testing options. Specialty patients also tend to require more tests over time, supporting continued growth in tests per accession and favorable mix.
Image Source: Zacks Investment Research
Strategic Acquisitions and Partnerships to Drive Growth: Labcorp continues to build relationships with health systems and regional laboratories, expanding its patient network and access to specialty testing. During the second quarter of 2026, the company completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics. It also secured another Department of Defense contract to provide testing across military hospitals worldwide. Net acquisitions added 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter. Labcorp invested $225.7 million in acquisitions, and management described the deal pipeline as very active. The expanded collaboration with Epic also places more than 6,500 Labcorp tests on the Aura platform, simplifying access for healthcare providers and supporting deeper integration with health-system customers.
Focus on Operational Efficiency: Labcorp is using technology, automation and artificial intelligence to improve productivity and customer access. Enterprise adjusted operating margin expanded 70 basis points year over year to 15.8% in the second quarter of 2026. Diagnostics margin increased 50 basis points to 18%, while BLS margin rose 130 basis points to 17%. Management attributed the gains to organic growth, operating efficiencies and actions within Early Development. The Launchpad program remains on track, and management expects enterprise, Diagnostics and BLS margins to improve for full-year 2026. Labcorp also launched the AI-powered MyLabcorp application, enhanced scheduling at patient service centers and expanded its Epic collaboration.
What Ails Labcorp?Macroeconomic and Cost Risks: Labcorp depends on testing demand from patients, physicians, hospitals and biopharmaceutical customers. Economic volatility, inflation, geopolitical disruption and tariffs can affect customer spending, supply costs and laboratory operations. The cost of revenues increased 5.6% year over year in the second quarter of 2026 and 5.4% during the first half. Although margins expanded, continued cost inflation could require further productivity gains or pricing actions to protect profitability.
Reimbursement and Cash-Flow Constraints: Changes in government and third-party reimbursement remain a risk for the company’s Diagnostics arm. Management estimated that Affordable Care Act-related changes reduced second-quarter 2026 diagnostic volume by 20-30 basis points and continues to assume a 30-basis-point full-year impact. The affected payer group represents less than 4-5% of diagnostic volume, but further coverage changes could weaken utilization or collections.
LH Stock Estimate TrendIn the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2026 earnings per share (EPS) has edged up 0.2% to $18.32.
The Zacks Consensus Estimate for 2026 revenues is pegged at $14.75 billion, implying 5.7% growth relative to the 2025 figure.
Key PicksSome better-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 35.3% compared with the industry’s 4.5% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 8.9% against the industry’s 28% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.6% compared with the industry’s 4.5% growth over the past year.
Labcorp Holdings Inc. (NYSE:LH – Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $320.99, but opened at $303.46. Labcorp shares last traded at $313.95, with a volume of 129,255 shares traded.
Trending Headlines about Labcorp Here are the key news stories impacting Labcorp this week:
Positive Sentiment: At its 2026 Investor Day, Labcorp highlighted potential acquisitions and continued investment in laboratory technology. These initiatives could expand its testing capabilities, improve efficiency and support longer-term revenue growth. Labcorp Holdings Eyes Acquisitions and Lab Tech Investment After 2026 Investor Day Positive Sentiment: Labcorp reaffirmed its long-term earnings outlook, signaling continued confidence in demand for clinical testing and its operating strategy. The company’s previously reported quarterly results also exceeded analyst expectations for earnings and revenue. Labcorp Reaffirms Long-Term Earnings Outlook Positive Sentiment: Baird raised its price target for Labcorp to $361 from $352 and maintained an Outperform rating, indicating that the analyst sees upside despite industry and reimbursement risks. Baird Adjusts Price Target on Labcorp Holdings Positive Sentiment: Seeking Alpha upgraded LH to Buy, citing resilient diagnostic demand, new test launches, a diversified biopharma business and solid operating margins. The analysis also noted that Labcorp had outperformed broad-market and healthcare peers year to date. Labcorp’s Future Driven by Clinical Testing Demand Neutral Sentiment: Recent performance coverage indicates LH has generally lagged some competitors in the latest session, even though longer-term performance comparisons remain favorable. Labcorp Stock Underperforms Competitors Negative Sentiment: Medicare’s signals regarding cuts to payment rates for laboratory services weighed on Labcorp and Quest Diagnostics. Investors are concerned that lower reimbursement could pressure revenue, margins and earnings, creating the most immediate reason for the stock’s weakness. Quest Diagnostics and Labcorp Shares Fall on Medicare Payment Concerns Analyst Ratings Changes LH has been the topic of a number of recent research reports. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. boosted their target price on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Piper Sandler increased their price target on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Robert W. Baird set a $352.00 price target on shares of Labcorp in a report on Friday, July 31st. Finally, Bank of America lifted their price objective on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $337.73.
Get Our Latest Report on Labcorp Labcorp Trading Down 2.4% The company has a 50 day moving average of $316.74 and a two-hundred day moving average of $283.82. The stock has a market capitalization of $24.65 billion, a PE ratio of 25.14, a P/E/G ratio of 1.77 and a beta of 0.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.
Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The company had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same period last year, the business posted $4.35 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current year.
Labcorp Announces Dividend The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 28th were paid a $0.72 dividend. The ex-dividend date was Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is 23.82%.
Insider Activity at Labcorp In other Labcorp news, EVP Bryan Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $66,968.46. Following the transaction, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kerrii Anderson sold 3,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. This represents a 31.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,919 shares of company stock worth $2,826,593 in the last 90 days. 0.84% of the stock is owned by insiders.
Hedge Funds Weigh In On Labcorp Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new position in shares of Labcorp in the fourth quarter valued at about $27,000. Allied Private Wealth LLC acquired a new stake in shares of Labcorp during the second quarter worth about $33,000. Cedar Mountain Advisors LLC lifted its holdings in shares of Labcorp by 786.7% during the first quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company’s stock worth $35,000 after purchasing an additional 118 shares during the period. SHP Wealth Management purchased a new stake in Labcorp in the fourth quarter valued at approximately $40,000. Finally, REAP Financial Group LLC boosted its position in Labcorp by 20.4% in the fourth quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock valued at $55,000 after buying an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.
Labcorp Company Profile (Get Free Report)
Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.
Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.
Further Reading Five stocks we like better than Labcorp Chips to Bots: Qualcomm’s Agentic AI Breakout Ciena Fell 40%—Now One Analyst Sees 50% Upside Energy Transfer Taps the AI Power Boom Viking’s Obesity Edge May Be Staying Power, Not Weight Loss Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.
Akcie Labcorp Holdings klesly o 3,3 % poté, co CMS oznámil snížení úhrad za laboratorní testy až o 15 % od 1. ledna 2027. Labcorp uvedl, že z CMS v roce 2025 pocházelo asi 8 % jeho tržeb.
Medical testing giant Labcorp Holdings (LH -2.66%) stock slipped 3.3% through 11:05 a.m. Tuesday, after the Centers for Medicare & Medicaid Services (CMS) disclosed Monday that they've been paying about 16% more for lab work than private insurers pay.
No longer.
Effective Jan. 1, 2027, CMS says it will cut reimbursement rates for lab costs by up to 15%.
Image source: Getty Images.
What this means for Labcorp (and for you) CMS estimates the reduced reimbursement rates will save taxpayers $1 billion per year. Unfortunately for Labcorp, though, these savings will come directly out of its own revenue stream.
In its latest 10-K filing with the SEC, Labcorp highlighted a reduction in the rates it receives from Medicare and Medicaid as one key risk to investing in Labcorp stock, warning that "its revenues, profitability, and cash flows may be materially impacted" by such an action by CMS. The question is: how badly might Labcorp be hurt?
And the answer: According to this same 10-K filing, Labcorp got approximately 8% of its revenue from CMS reimbursement in 2025.
Premium Feature
Moneyball Superscore
78/100
Today's Change
(
-2.66
%) $
-8.55
Current Price
$
312.44
What's next for Labcorp? And now we can do a little math. A 15% reduction to an 8% revenue stream implies that if CMS reduces its rates by the full 15%, Labcorp's annual revenue would decrease by 1.2%. Now, Labcorp notes that successive 15% per year reductions are possible from 2027 through 2029. This still implies that the worst-case scenario for Labcorp is about a 3.6% reduction in its business.
With Labcorp stock down 3.3%, that worst-case scenario has been just about priced into the stock today. From where I sit, that means there's little reason to expect Labcorp stock to keep going down after today.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Labcorp Holdings Inc. (LH) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDT
Company Participants
Adam Schechter - President, CEO & Chairman
Julia Wang - CFO & Executive VP
Conference Call Participants
Erin Wilson Wright - Morgan Stanley, Research Division
Presentation
Erin Wilson Wright
Morgan Stanley, Research Division
Good afternoon, everyone, and welcome to the Morgan Stanley Global Healthcare Conference. I'm Erin Wright, the lead health care services analyst at Morgan Stanley. For more important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures.
And with that, we're happy to have Labcorp with us today, hot on the heels of their Investor Day last week, CEO, Adam Schechter; as well as CFO, Julia Wang, are with us today. Thank you so much for joining us.
Question-and-Answer Session
Erin Wilson Wright
Morgan Stanley, Research Division
Let's kick it off with just a bigger picture question on the back of the Investor Day. Some of your high-level takeaways that you wanted to drive home for investors. You reaffirmed the long-term kind of guide or largely reaffirmed the long-term guide with some tweaks. And can you kind of break down some of those building blocks and how you think about the long term for Labcorp?
Adam Schechter
President, CEO & Chairman
Absolutely. Good afternoon, everybody. Erin, thanks for having us. It's a pleasure to be here. So last week, we had our Investor Day. And the first thing we did was we showed data on the last 3 years when we provided longer-term guidance and showed that we were able to achieve exactly what we committed to achieving.
The second thing we did was we reaffirmed our guidance for the rest of 2026, which we feel very strongly about, remains compelling, and we reaffirmed that guidance. The third thing we did
Labcorp uspořádal Investor Day 2026, na kterém CEO a předseda představenstva Adam Schechter představil strategii, odlišení na trhu a cesty k růstu společnosti.
Labcorp Holdings Inc. (LH) Analyst/Investor Day September 10, 2026 9:00 AM EDT
Company Participants
Dewey Steadman - Senior Vice President of Investor Relations
Adam Schechter - President, CEO & Chairman
Bryan Vaughn - EVP & President of Diagnostics
Brian Caveney - Exec VP, President of Biopharma Laboratory Services & Chief Medical and Scientific Officer
Shakti Ramkissoon
Akinbolade Oyegunwa - Executive VP and Chief Information & Technology Officer
Julia Wang - CFO & Executive VP
Conference Call Participants
David MacDonald - Truist Securities, Inc., Research Division
Lisa Gill - JPMorgan Chase & Co, Research Division
Erin Wilson Wright - Morgan Stanley, Research Division
Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division
Michael Cherny - Leerink Partners LLC, Research Division
Lu Li - BofA Securities, Research Division
David Westenberg - Piper Sandler & Co., Research Division
Pito Chickering - Deutsche Bank AG, Research Division
Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division
Kevin Caliendo - UBS Investment Bank, Research Division
Presentation
Operator
Good morning, everyone. We're going to get started. Please welcome Dewey Steadman, Senior Vice President, Investor Relations.
Dewey Steadman
Senior Vice President of Investor Relations
So welcome, everyone. I'm not mic'd up. Welcome, everyone, to Labcorp's 2026 Investor Day. Before we get started, please note that our presentations will include forward-looking statements. These statements are subject to change based on various factors, many of which are beyond our control. More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other filings with the SEC.
Our presentation today will include adjusted financial measures, and please see the use of adjusted measures section within our presentation for more information about the use of adjusted non-GAAP financial measures.
We'll kick off today's Investor Day with our Chairman and CEO, Adam Schechter, outlining our strategy, market differentiation and avenues for enterprise growth. Then we'll have business
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m. ET, where the company will provide an in-depth review of its growth strategy, innovation roadmap and long-term financial outlook. The event will highlight Labcorp's unique position at the intersection of diagnostics, biopharma, science and technology and how the company is creating long-term value for customers and shareholders.
"Labcorp has never been more relevant than it is today," said Adam Schechter, Chairman and CEO of Labcorp. "The healthcare landscape is being transformed by scientific innovation, personalized medicine and consumer-directed care, and the strengths of Labcorp will help shape the future of healthcare. Labcorp's growth strategy supports our expectation for above-market performance and underpins our long-term outlook through 2029 of compound annual growth of 5% to 8% in revenue and 8.5% to 11.5% in adjusted earnings per share."
Strategic Priorities Focused on High-Growth Areas
At Investor Day, Labcorp will highlight the four strategic priorities that are driving its next phase of growth and strengthening its leadership position across the healthcare ecosystem. These priorities are:
Leading in specialty testing through continued innovation in oncology, neurology, autoimmune diseases and women's health. Being a partner of choice for health systems and leading pharmaceutical companies through differentiated scientific and operational capabilities. Driving personalized health solutions using science and insights to help develop therapies, inform therapy selection and deliver tailored experiences at scale. Shaping the company's future through advanced technology, including artificial intelligence and robotics. Long-Term Financial Outlook
In addition to reaffirming its 2026 guidance, Labcorp will discuss its outlook through 2029. Specifically, the company expects to achieve:
Compound annual revenue growth between 5% and 8% Adjusted operating margin expansion between 75 and 150 basis points by the end of 2029 Compound annual adjusted EPS growth between 8.5% and 11.5% Compound annual free cash flow growth in line with adjusted earnings growth "Our confidence in this outlook is grounded in a proven record of delivering on our commitments and a disciplined value creation framework that converts growth into earnings, cash flow and shareholder returns," said Julia Wang, Executive Vice President and Chief Financial Officer.
Webcast
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 9 a.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
Guidance for 2026
Labcorp is affirming 2026 full-year guidance, last updated on July 30, 2026. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.
2026 Guidance
Low
High
Revenue
Labcorp Enterprise (1)(2)
$14,710
$14,827
Growth (3)
5.4 %
6.3 %
Diagnostics Laboratories
$11,450
$11,532
Growth (3)
5.3 %
6.0 %
Biopharma Laboratory Services (4)
$3,269
$3,300
Growth (3)
5.5 %
6.5 %
Adjusted EPS
$18.10
$18.55
Free Cash Flow
$1,240
$1,360
(1) 2026 Enterprise guidance includes an impact from foreign currency translation of 0.4%.
(2) Enterprise level revenue is presented net of intercompany transaction eliminations.
(3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million, and Biopharma Laboratory Services revenue of $3,098 million.
(4) 2026 Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Use of Adjusted Measures
The company has provided in this press release "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted EPS (or adjusted net income per share), adjusted operating margin, and free cash flow. Moreover, the company is not able to provide reconciliations of these adjusted measures on a forward-looking basis because it is unable to predict, without unreasonable effort, certain components thereof. As such, any associated estimate and its impact on these measures could vary materially, and the company cannot address the probable significance of unavailable information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies.
Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures prepared in accordance with GAAP, and these adjusted measures may be different from and not directly comparable to the measures presented by other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance, the long-term financial outlook, and the long-term capital deployment strategy, and related assumptions of each, (ii) the impact of various factors on operating and financial results, including global economic and market conditions, on the company's businesses, operating results, cash flows, and/or financial condition, (iii) current and future offerings, capabilities, and business strategies, including those related to high-growth specialty areas, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions, partnerships, company initiatives and investments, (v) the use of technology, including the use of artificial intelligence (AI), and expected operational efficiencies, revenue growth, impacts on customer and patient experience and access, and other benefits from the use of such technologies, and (vi) opportunities for future growth.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer preferences and purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failures of, or adverse events relating to, the company's information technology systems, programs, or processes or the company's data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
Labcorp koupila MLM Medical Labs a rozšířila globální síť centrálních laboratoří pro klinické studie na čtyři kontinenty. Získává tím silnější biomarkerové a specializované testování.
Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed.
The acquisition enhances Labcorp's position as a leading independent central laboratory services provider by expanding its presence in key clinical research regions and strengthening its biomarker and specialty testing capabilities. The transaction expands Labcorp's laboratory footprint and establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa. The combination brings together Labcorp's global scale, breadth of scientific capabilities and operational infrastructure with MLM's established laboratory network and science-led service model.
"Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programs," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies. Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide."
This integrated global infrastructure enhances Labcorp's ability to support complex multinational clinical trials with consistent scientific, operational and regulatory oversight from a single trusted partner. The acquisition also expands Labcorp's laboratory footprint in critical clinical research markets, including Africa, where MLM operates the continent's first fully CAP-accredited central laboratory.
In addition, the acquisition strengthens Labcorp's scientific and regulatory expertise and broadens access to biomarker and specialty testing capabilities that support increasingly complex clinical development programs.
This acquisition reflects Labcorp's ongoing commitment to investing in central laboratory services and meeting the evolving needs of clinical trial sponsors worldwide.
Evercore served as exclusive financial advisor to Labcorp and Pierson Ferdinand and Hogan Lovells served as Labcorp's legal counsel.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the acquisition of MLM Medical Labs and how its capabilities are anticipated to benefit clinical trial sponsors.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
Labcorp rozšiřuje specializované testování v onkologii, ženském zdraví, autoimunitních chorobách a neurologii, což podpořilo růst tržeb. Rizikem zůstávají změny úhrad a rostoucí náklady.
Key Takeaways Labcorp is expanding specialty testing in oncology, women's health, autoimmune disease and neurology.Acquisitions and partnerships added to revenue growth and expanded Labcorp's health-system reach.Reimbursement changes and rising costs could pressure LH's Diagnostics utilization and profitability. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is set to benefit from the expansion of its testing capabilities in strategic high-growth areas, including neurology and autoimmune disease. The company’s efforts to enhance its partnership with hospitals and health care systems have strengthened its footprint in important markets. Solid financial health also adds to the stock’s appeal. Yet, broader economic pressures and reimbursement-related headwinds may weigh on its results.
Over the past year, this Zacks Rank #3 (Hold) stock has risen 21.9% compared with the 13.4% growth of the industry and a 20.8% rise of the S&P 500 composite.
The renowned healthcare diagnostics company has a market capitalization of $27.28 billion. Labcorp’s earnings yield of 5.4% favorably compares with the industry’s 3.9% yield. In the trailing four quarters, the company delivered an average earnings surprise of 3.1%.
Let’s delve deeper.
Tailwinds for LabcorpTargeted Development in High-Growth Areas: Labcorp continues to expand in specialty testing areas such as oncology, women’s health, autoimmune disease and neurology. These areas delivered double-digit revenue growth during the first half of 2026 and helped the company win new health-system and provider customers.
In oncology, Labcorp launched ColoSense nationwide, expanded companion diagnostic access for prostate cancer and added an advanced DPYD genotyping test. It also entered into a clinical trial collaboration to evaluate Plasma Detect Genome MRD in patients at risk of early-stage lung cancer recurrence. The consumer business maintained double-digit growth, supported by Labcorp OnDemand, Marker by Labcorp and new at-home testing options. Specialty patients also tend to require more tests over time, supporting continued growth in tests per accession and favorable mix.
Image Source: Zacks Investment Research
Strategic Acquisitions and Partnerships to Drive Growth: Labcorp continues to build relationships with health systems and regional laboratories, expanding its patient network and access to specialty testing. During the second quarter of 2026, the company completed acquisitions of select Parkview Health outreach laboratory services and Tribal Diagnostics. It also secured another Department of Defense contract to provide testing across military hospitals worldwide.
Net acquisitions added 1.2% to enterprise revenue growth and 1.9% to Diagnostics growth during the quarter. The expanded collaboration with Epic also places more than 6,500 Labcorp tests on the Aura platform, simplifying access for healthcare providers and supporting deeper integration with health-system customers.
Solvency, Buybacks and Dividends: Labcorp ended the second quarter of 2026 with cash and cash equivalents of $141.8 million. Short-term borrowings and the current portion of long-term debt were $0.9 million, much lower than the cash level. The company also retired $500 million of senior notes during the quarter. Labcorp repurchased $353.8 million of stock and paid $58.7 million in dividends during the second quarter. In July 2026, the board increased the share-repurchase authorization by $1 billion, bringing the remaining authorization to $1.4 billion.
What Ails Labcorp?Macroeconomic and Cost Risks: Labcorp depends on testing demand from patients, physicians, hospitals and biopharmaceutical customers. Economic volatility, inflation, geopolitical disruption and tariffs can affect customer spending, supply costs and laboratory operations. The cost of revenues increased 5.6% year over year in the second quarter of 2026 and 5.4% during the first half. Although margins expanded, continued cost inflation could require further productivity gains or pricing actions to protect profitability. The biopharmaceutical business also remains exposed to changes in research budgets, study timing and customer funding, particularly within smaller biotech companies and Early Development programs.
Reimbursement and Cash Flow Constraints: Changes in government and third-party reimbursement remain a risk for the Diagnostics arm. Management estimated that Affordable Care Act-related changes reduced second-quarter 2026 diagnostic volume by 20-30 basis points and continues to assume a 30-basis-point full-year impact. The affected payer group represents less than 4-5% of diagnostic volume, but further coverage changes could weaken utilization or collections.
LH Stock Estimate TrendIn the past 30 days, the Zacks Consensus Estimate for Labcorp’s 2026 earnings per share (EPS) has edged up 1.6% to $18.28.
The Zacks Consensus Estimate for 2026 revenues is pegged at $14.75 billion, implying 5.7% growth relative to the 2025 figure.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 37% against the industry’s 2.7% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 40.3% against the industry’s 2.7% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 8.5% against the industry’s 2.7% decline over the past year.
Labcorp začne nabízet první FDA schválený krevní test Elecsys pTau-217 pro detekci amyloidní patologie spojené s Alzheimerovou chorobou u lidí od 55 let. Test má být dostupný v primární i specializované péči.
Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings Measures phosphorylated Tau 217 (pTau-217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease Intended for individuals 55 and older with signs, symptoms or complaints of cognitive decline , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys® pTau-217 test following clearance by the U.S. Food and Drug Administration (FDA). Developed by Roche Diagnostics, the blood test aids in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 and older with signs, symptoms or complaints of cognitive decline. Elecsys® pTau-217 is the first and only FDA-cleared single-biomarker blood test to both rule in and rule out amyloid pathology across specialty and primary care settings
Photo courtesy of Labcorp For many individuals experiencing cognitive decline, evaluation for Alzheimer's disease often involves multiple tests, care settings and healthcare providers. As blood-based biomarkers for neurological conditions continue to advance, pTau-217 has emerged as a leading biomarker to help clinicians rule in or rule out amyloid pathology in people presenting with symptoms or concerns of cognitive decline. While several pTau-217 assays are commercially available, standardization across care settings remains an important consideration for clinicians. The Elecsys® pTau-217 test provides a single, standardized assay with the same clinically validated cutoffs across primary and specialty care settings, supporting a consistent approach to patient assessment.
"The best advances in Alzheimer's disease testing should make the diagnostic process simpler, more accessible and more consistent for both patients and clinicians," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "For individuals and families seeking answers about cognitive changes, the path to evaluation can be long and uncertain. By making the Elecsys® pTau-217 test available nationwide, Labcorp is expanding access to innovative blood-based testing and helping clinicians provide more timely assessments and informed next steps for patients."
Key Features of the Elecsys® pTau-217 Test
Uses the same clinical cutoffs across primary and specialty care settings, providing a standardized approach to patient assessment. Provides positive, intermediate and negative result categories to support assessment of the likelihood of amyloid pathology. Offers a convenient, minimally invasive blood-based testing option with performance comparable to cerebrospinal fluid (CSF) testing and positron emission tomography (PET) imaging. Once ordered by a clinician, patients can have their blood drawn in a physician's office or at one of Labcorp's more than 2,200 patient service centers nationwide. Results are interpreted alongside clinical information and other relevant findings as part of a comprehensive evaluation. Advancing Labcorp's Alzheimer's Disease Testing Portfolio
The addition of Elecsys® pTau-217 expands Labcorp's Alzheimer's disease testing portfolio. The test joins Labcorp's existing offerings, including the FDA-cleared Elecsys® pTau-181 test and the Lumipulse® pTau-217/Beta-Amyloid 42 Ratio.
Labcorp plans to make the test available nationwide in the coming months. For more information about Labcorp's Alzheimer's disease testing, visit https://www.labcorp.com/treatment-areas/neurology/conditions/neurodegenerative/alzheimers.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected availability, utility, and benefits of the Elecsys® pTau217 test to detect Alzheimer's disease pathology.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
Labcorp vstupuje do druhé poloviny roku 2026 s rychlejším růstem tržeb, širšími maržemi a vyšším výhledem na celý rok díky silné poptávce po specializovaném testování. Akcie ale obchodují s prémií vůči historickému ocenění, což zvyšuje riziko zklamání.
Key Takeaways Labcorp enters the second half of 2026 with faster revenue growth, wider margins and higher guidance. LH's specialty testing and Biopharma Laboratory Services are supporting growth and profitability. Labcorp trades above its five-year median valuation, leaving less room for execution misses. Labcorp Holdings Inc. (LH - Free Report) is entering the second half of 2026 with faster revenue growth, wider margins and higher full-year guidance. Specialty testing and Biopharma Laboratory Services are adding operating support while efficiency programs are helping profitability.
The trade-off is valuation. LH now carries a premium to both its five-year median and its Zacks sub-industry multiple, leaving less room for execution misses. That backdrop favors a measured view of the shares.
Labcorp’s Specialty Mix Supports the Bull CaseSpecialty testing remains a central growth driver. Oncology, women’s health, autoimmune disease and neurology produced double-digit revenue growth in the first half of 2026, helping Labcorp win health-system and provider customers.
Per the Zacks Consensus Estimate, the company’s 2026 revenues are expected to grow 5.6% year over year.
Image Source: Zacks Investment Research
The company also expanded its test menu and access points. New oncology offerings, a broader Epic collaboration and additional health-system relationships can support test utilization and a favorable mix because specialty patients often require more testing over time. Quest Diagnostics Incorporated (DGX - Free Report) is a relevant diagnostics peer, with a broad testing portfolio that includes specialty and oncology services.
LH’s Margin Gains Improve Earnings QualitySecond-quarter adjusted operating margin expanded 70 basis points year over year to 15.8%. Diagnostics margin rose 50 basis points to 18%, while Biopharma Laboratory Services margin increased 130 basis points to 17%.
Labcorp attributed the gains to organic growth, operating efficiencies and actions within Early Development. Launchpad, automation, artificial intelligence and other technology initiatives remain part of the productivity effort. Medpace Holdings, Inc. (MEDP - Free Report) , a full-service clinical research organization with central laboratory capabilities, provides a useful comparison point for the competitive biopharma-services landscape.
Labcorp’s Valuation Leaves Less Room for ErrorLH trades at 16.7X forward 12-month earnings, above the Zacks sub-industry multiple of 16.2X and its own five-year median of 14.4X. The current multiple is also closer to the upper end of its five-year range of 10.5X to 17.8X.
Image Source: Zacks Investment Research
That premium raises the bar for execution. Continued earnings growth, margin expansion and delivery against the raised 2026 outlook become more important when investors are paying above the stock’s historical median valuation.
LH Still Faces Reimbursement and Cost RisksReimbursement remains a constraint for Diagnostics. Affordable Care Act-related changes reduced second-quarter diagnostic volume by an estimated 20-30 basis points, and Labcorp continues to assume a 30-basis-point full-year effect. Pressure tied to Protecting Access to Medicare Act reimbursement is another risk.
Cost inflation, tariffs, currency swings and competition add uncertainty. Cost of revenues rose 5.6% year over year in the second quarter, while full-year guidance includes foreign-currency benefits to enterprise and Biopharma Laboratory Services growth. A reversal in exchange rates could make the outlook harder to achieve.
Labcorp’s Ratings Point to a Balanced SetupThe operating picture has improved, but the valuation premium argues against treating the recent momentum as an automatic buy signal. Labcorp currently carries a Zacks Rank #3 (Hold), which is consistent with a more balanced near-term stance than the stronger buy-rated categories.
Its Value Score of B, Growth Score of C and Momentum Score of A produce a VGM Score of B. The A Momentum Score reflects favorable price and estimate-revision characteristics, while the C Growth Score keeps the broader profile mixed. Zacks Style Scores are designed to complement the Zacks Rank, and a #3 ranking can still be held when the overall setup remains acceptable. The combination supports patience rather than chasing the shares at a premium.
You can see the complete list of today’s Zacks #1 Rank stocks here.
FDA schválila test Labcorp PGDx elio tissue complete CDx jako doprovodnou diagnostiku pro identifikaci pacientů s pokročilým melanomem s variantami BRAF V600E/K. Test má pomoci vybrat ty, kteří mohou mít prospěch z cílené léčby.
Labcorp's FDA‑approved PGDx elio® tissue complete CDx helps identify advanced melanoma patients with certain BRAF variants eligible for BRAF and BRAF/MEK inhibitor therapies Supports access to targeted treatment options for the deadliest form of skin cancer , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that the U.S. Food and Drug Administration (FDA) has approved Labcorp's PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapiesi.
Addressing a Critical Need in Advanced Melanoma
Melanoma is the deadliest form of skin cancer, with a five‑year survival rate of just 16% for patients diagnosed with stage IV disease. However, targeted therapies are an important treatment option for patients with advanced melanoma whose tumors have a BRAF alteration. As a companion diagnostic, PGDx elio tissue complete CDx helps clinicians identify which melanoma patients carry these BRAF V600E/K variants and may benefit from treatment with FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination regimens.
"Advanced melanoma is an extremely aggressive and life‑threatening cancer, but targeted treatments are offering real hope for patients," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "Labcorp's FDA‑approved companion diagnostic improves access to these therapies by allowing clinicians to confirm which patients may be eligible for and can start receiving those treatments as soon as possible."
A Comprehensive and Scalable Testing Solution
Labcorp's PGDx elio tissue complete CDx is approved for use by qualified healthcare professionals across hospitals and clinical laboratories, supporting broader patient access to high-quality molecular testing. As a kit-based solution, the companion diagnostic can be implemented directly within hospitals and health systems, expanding access to testing while enabling organizations to retain samples and data that may inform future clinical research.
The addition of Labcorp's PGDx elio tissue complete CDx reflects the continued expansion of Labcorp's precision medicine portfolio, which includes comprehensive tissue- and liquid-based oncology diagnostics designed to support personalized care. For more information about PGDx elio tissue complete or Labcorp's oncology solutions, visit https://www.labcorp.com/oncology/providers/testing-solutions/kitted-solutions/pgdx-elio-tissue-complete-cdx.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
iPGDx elio tissue complete CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with targeted therapies listed below in accordance with the approved therapeutic product labeling.
PGDx elio tissue complete CDx Indications
Indication: Melanoma
Biomarker: BRAF V600E/ BRAF V600K
Therapy: BRAF inhibitors approved by FDA or BRAF/MEK inhibitor combinations approved by FDA
Key Takeaways Labcorp shares gained 14% in a month as earnings, revenues and operating margins improved. Specialty testing posted double-digit growth in oncology, women's health, autoimmune disease and neurology.Labcorp trades at 16.7X forward earnings, above its 14.4X five-year median but below its 17.8X high. Labcorp Holdings Inc. (LH - Free Report) shares have gained 14% in the past month, sharpening the debate over how much upside remains after a rapid advance. The rally comes as the company is reporting better earnings, expanding margins and growth across both Diagnostics Laboratories and Biopharma Laboratory Services.
The operating picture has improved, but valuation has moved above Labcorp’s longer-term norm. That leaves investors weighing execution and business momentum against a higher bar for future results.
Labcorp’s One-Month Rally Sets a Higher BarLabcorp’s 14% four-week gain stands out against an already stronger operating backdrop. The company’s Diagnostics Laboratories business grew revenues 5.5% year over year in the second quarter, while Biopharma Laboratory Services, or BLS, advanced 6.5%.
The move does not establish that any single development drove the stock higher. It does, however, raise expectations as investors assess whether improving profitability, specialty testing demand and biopharma activity can sustain the recent momentum.
LH’s Q2 Results Add Fundamental SupportSecond-quarter adjusted earnings were $4.99 per share, up 14.9% year over year and 4.2% above the Zacks Consensus Estimate. Revenues increased 5.8% to $3.73 billion and also topped the consensus mark.
Profitability improved with the top line. Adjusted operating income rose to $588.7 million from $531.6 million, while the enterprise adjusted operating margin expanded 70 basis points to 15.8%. The margin gain shows that revenue growth is translating into better operating leverage.
In the past 30 days, Labcorp’s 2026 earnings have moved north by 1.3% to $18.24.
Image Source: Zacks Investment Research
Labcorp’s Growth Drivers Still Have Room to RunSpecialty testing remains a central growth engine. Oncology, women’s health, autoimmune disease and neurology each delivered double-digit revenue growth during the first half of 2026, supporting new health-system and provider wins and a favorable test mix.
BLS adds another source of momentum. Second-quarter revenue rose 6.5% to $836.2 million, Central Laboratories revenue increased 9.8% and the segment’s adjusted operating margin reached 17%. Quest Diagnostics Incorporated (DGX - Free Report) , another large diagnostic testing provider, offers investors a direct industry comparison for laboratory demand and health-system relationships. Thermo Fisher Scientific Inc. (TMO - Free Report) also provides a relevant biopharma-services reference point through its broad pharmaceutical and clinical research capabilities.
LH’s Valuation Raises the Priced-In QuestionLabcorp trades at 16.7X forward 12-month earnings, modestly above the Zacks sub-industry’s 16.2X multiple. It also sits well above its own five-year median of 14.4X, although the current multiple remains below the five-year high of 17.8X.
Image Source: Zacks Investment Research
That premium does not negate the company’s improving results, but it reduces the room for disappointment. Further upside will likely require continued earnings execution, sustained specialty and BLS growth and additional margin progress to justify a valuation already above Labcorp’s longer-term norm.
Labcorp’s Ratings Favor Momentum Over GrowthThe near-term setup is balanced rather than one-sided. Labcorp currently carries a Zacks Rank #3 (Hold), which points to a neutral short-term earnings-revision backdrop rather than a clear buy or sell signal.
The Style Scores tilt more favorably toward momentum and value. Labcorp has a VGM Score of B, Momentum Score of A and Value Score of B, while its Growth Score is C. The mix fits the current tension: price momentum and valuation characteristics are favorable, but the pure-growth profile is less compelling. After the recent rally, execution remains important as investors weigh business progress against a richer valuation.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Labcorp spustila celostátní dostupnost FDA schváleného testu VENTANA PTEN (SP218) RxDx pro rakovinu prostaty. Test pomáhá určit pacienty, kteří mohou být vhodní pro léčbu TRUQAP v kombinaci s abirateronem a prednisonem.
First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib)
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.
Addressing an Unmet Need in Prostate Cancer Care
Excluding skin cancer, prostate cancer is the most common cancer among men in the United States, with more than 330,000 new cases expected each year. PTEN is a tumor suppressor protein that plays a critical role in regulating cell growth. Loss of PTEN protein expression has been associated with more aggressive disease progression and reduced benefit from current standard-of-care therapies in prostate cancer. Until recently, there were no approved treatment options specifically targeting this biology.
The VENTANA PTEN (SP218) RxDx Assay is a companion diagnostic designed to detect PTEN protein loss in prostate cancer tissue specimens, providing clinicians with important biomarker information to help guide treatment decisions and support personalized patient care.
"Biomarker testing is essential to advancing precision oncology and helping connect patients with the therapies most appropriate for their disease," said Shakti Ramkissoon, M.D., Ph.D., vice president, medical lead for oncology at Labcorp. "The launch of the VENTANA PTEN (SP218) RxDx Assay underscores how Labcorp is expanding access to innovative companion diagnostics and delivering the timely insights physicians need to make personalized treatment decisions."
Advancing Access to FDA-Approved Companion Diagnostics
Labcorp participated in Roche's early access program to support Day 1 laboratory readiness for the assay, reinforcing the company's commitment to helping patients gain timely access to newly approved targeted therapies and the companion diagnostics needed to identify eligible patients.
The VENTANA PTEN (SP218) RxDx Assay is now available through Labcorp's national network of laboratories and complements the company's comprehensive portfolio of genomic, molecular and companion diagnostic testing services that support precision oncology care. As one of the nation's largest providers of oncology testing services, Labcorp enables physicians across community and academic settings to access FDA-approved companion diagnostics at scale, helping bring precision medicine to more patients regardless of where they receive care. The assay can also be ordered alongside Labcorp's broader portfolio of oncology testing services, providing clinicians with comprehensive biomarker insights from a single laboratory partner.
To learn more about the assay, visit https://oncology.labcorp.com/tests/484680/PTEN-IHC-with-interpretation-for-prostate-adenocarcinoma
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Labcorp Holdings zveřejní hospodářské výsledky za 2. čtvrtletí 2026, zaměří se na upravené výsledky, kapitálovou alokaci a aktualizovaný celoroční výhled pro rok 2026.
Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call July 30, 2026 9:00 AM EDT
Company Participants
Dewey Steadman
Adam Schechter - President, CEO & Chairman
Julia Wang - CFO & Executive VP
Conference Call Participants
Lisa Gill - JPMorgan Chase & Co, Research Division
Kevin Caliendo - UBS Investment Bank, Research Division
Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division
Michael Cherny - Leerink Partners LLC, Research Division
Jack Meehan
Michael Ryskin - BofA Securities, Research Division
David Westenberg - Piper Sandler & Co., Research Division
Pito Chickering - Deutsche Bank AG, Research Division
Erin Wilson Wright - Morgan Stanley, Research Division
Ann Hynes - Mizuho Securities USA LLC, Research Division
Tycho Peterson - Jefferies LLC, Research Division
Anna Kruszenski - Barclays Bank PLC, Research Division
Yujin Park - Robert W. Baird & Co. Incorporated, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q2 2026 Labcorp Holdings Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Dewey Steadman, Senior Vice President, Investor Relations. Please go ahead.
Dewey Steadman
Good morning, and welcome to Labcorp's Second Quarter 2026 Financial Results Webcast. With me today are Adam Schechter, our Chairman and Chief Executive Officer; and Julia Wang, our Executive Vice President and Chief Financial Officer. This morning, in the Events section of the Labcorp Investor Relations website at ir.labcorp.com, we posted both our press release and a supplemental financial presentation with additional information on our business and operations. We will also post a replay of this webcast on the IR website for 1 year.
On today's webcast, we will focus on our adjusted or non-GAAP results for the second quarter of 2026, our capital allocation strategy and our updated financial guidance for the full year 2026. Our GAAP results
Labcorp ve 2. čtvrtletí zvýšil tržby na 3,73 miliardy USD a upravený zisk na akcii (EPS) na 4,99 USD. Zároveň navýšil celoroční výhled tržeb i upraveného zisku na akcii (EPS).
Results from operations for second quarter 2026 versus second quarter 2025: Revenue: $3.73 billion vs. $3.53 billion, up 5.8% Diluted EPS: $3.64 vs. $2.84, up 28.5% Adjusted EPS: $4.99 vs. $4.35, up 14.9% Raised full-year enterprise revenue growth and adjusted EPS guidance: Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.
"Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business," said Adam Schechter, Chairman and CEO of Labcorp. "During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders."
Labcorp continues to advance its strategic priorities:
Lead in specialty testing, with several advancements in Labcorp Oncology:
Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity. Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense's primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio. Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp's Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence. Expanded nationwide access to Roche's FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca's targeted therapy TRUQAP. Be a partner of choice for health systems and regional/local laboratories:
Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide. Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio. Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas. Grow Consumer Health:
Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source. Introduced Canada's first at-home, self-collection test to measure women's fertility-related hormones and men's testosterone levels. Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health. Shape our future through technology and innovation:
Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic's Aura platform. Enhanced the patient experience at Labcorp's Patient Service Centers, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance. Labcorp also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. The company also paid down $500.0 million in senior notes in June. On July 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record at the close of business on August 28, 2026. In July, the Board of Directors approved an increase of $1.0 billion in the company's share repurchase authorization, bringing the remaining total authorization to $1.4 billion.
LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
Delta
2026
2025
Delta
Revenue Summary (Dollars in millions)
Total Revenue
$ 3,731.1
$ 3,527.3
5.8 %
$ 7,268.7
$ 6,872.4
5.8 %
Organic(1)
4.2 %
3.6 %
Acquisitions, net of Divestitures(2)
1.2 %
1.3 %
Foreign Exchange
0.4 %
0.9 %
(1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.
(2) Includes the impact from strategic actions taken in Early Development.
Earnings Summary (Dollars in millions, except per share data)
Operating Income ("OI")
$ 451.6
$ 394.5
$ 832.4
$ 720.5
OI as % of Revenue
12.1 %
11.2 %
90 bps
11.5 %
10.5 %
100 bps
Adjustments (3)
$ 137.1
$ 137.1
$ 264.2
$ 280.1
Adjusted Operating Income ("AOI") (4)
$ 588.7
(5)
$ 531.6
$ 1,096.6
$ 1,000.6
AOI as % of Revenue
15.8 %
(5)
15.1 %
70 bps
15.1 %
14.6 %
50 bps
Net Earnings Attributable to Labcorp
Holdings Inc.
$ 298.7
$ 237.9
$ 576.5
$ 450.7
Diluted EPS
$ 3.64
$ 2.84
$ 6.99
$ 5.36
Adjusted EPS (4)
$ 4.99
$ 4.35
14.9 %
$ 9.24
$ 8.19
12.8 %
(3) Adjustments include amortization, impairment charges, restructuring charges, and special items.
(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies.
LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED RESULTS
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Cash Flow Summary (Dollars in millions)
Operating Cash Flow
$ 445.5
$ 620.6
$ 637.0
$ 639.1
Capital Expenditures
131.6
77.9
252.6
203.9
Free Cash Flow
$ 313.9
(1)
$ 542.7
$ 384.4
$ 435.2
(1) The difference in free cash flow was primarily due to working capital timing and planned increases in capital expenditures.
Capital Allocation Summary
At the end of the quarter, Labcorp's cash and cash equivalents balance was $141.8 million and total debt was $5.86 billion. In June, we retired $500.0 million in senior notes. During the quarter, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. LABCORP HOLDINGS INC. AND SUBSIDIARIES
Diagnostics Laboratories Segment Summary
Three Months Ended June 30,
2026
2025
Delta
Revenue Summary (Dollars in millions)
Total Revenue
$ 2,900.7
$ 2,748.8
5.5 %
Organic
3.6 %
Acquisitions, net of Divestitures
1.9 %
Earnings Summary (1) (Dollars in millions)
Adjusted Operating Income ("AOI") (2)
$ 522.6
(3)
$ 482.8
AOI as % of Revenue
18.0 %
(3)
17.6 %
50 bps
(1) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.
(3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies.
Three Months Ended June 30, 2026
Requisition
Price/Mix
Volume Delta (4)
Delta (4)
Metrics Summary
Total
3.0 %
2.5 %
Organic (5)
1.8 %
1.8 %
Acquisitions, net of Divestitures
1.3 %
0.6 %
Foreign Exchange
— %
— %
(4) Column shows changes versus the three months ended June 30, 2025.
(5) Organic price/mix includes lab management agreements.
LABCORP HOLDINGS INC. AND SUBSIDIARIES
Biopharma Laboratory Services Segment Summary
Three Months Ended June 30,
2026
2025
Delta
Revenue Summary (Dollars in millions)
Total Revenue
$ 836.2
$ 784.8
6.5 %
(1)
Organic(2)
6.2 %
Acquisitions, net of Divestitures(3)
(1.4) %
Foreign Exchange
1.8 %
(1) Central Labs revenue growth of 9.8%; Early Development revenue was down 1.4%.
(2) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.
(3) Includes the impact from strategic actions taken in Early Development.
Earnings Summary (4) (Dollars in millions)
Adjusted Operating Income ("AOI") (5)
$ 142.2
(6)
$ 123.3
AOI as % of Revenue
17.0 %
(6)
15.7 %
130 bps
(4) Non-GAAP financial measure. See "Reconciliation of Non-GAAP Measures" for additional information.
(5) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.
(6) Adjusted Operating Income and margin increased, driven by organic growth and operating efficiencies from the strategic actions taken in Early Development.
As of
June 30, 2026
Metrics Summary (Dollars in billions)
TTM Net Orders
$ 3.32
TTM Book to Bill
1.03
Backlog
$ 8.73
(7)
Next Twelve Months Forecast Backlog Conversion
$ 2.75
(7) Backlog increased 0.2% compared to this period last year.
Guidance for 2026
Labcorp is updating 2026 full year guidance to reflect its second quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.
(Dollars in millions, except per share data)
Previous
Updated
2026 Guidance
2026 Guidance
Low
High
Low
High
Revenue
Labcorp Enterprise (1)(2)
$14,649
$14,803
$14,710
$14,827
Growth (3)
5.0 %
6.1 %
5.4 %
6.3 %
Diagnostics Laboratories
$11,431
$11,518
$11,450
$11,532
Growth (3)
5.1 %
5.9 %
5.3 %
6.0 %
Biopharma Laboratory Services (4)
$3,216
$3,266
$3,269
$3,300
Growth (3)
3.8 %
5.4 %
5.5 %
6.5 %
Adjusted EPS
$17.70
$18.35
$18.10
$18.55
Free Cash Flow
$1,240
$1,360
$1,240
$1,360
(1) 2026 Updated Enterprise guidance includes an impact from foreign currency translation of 0.4%.
(2) Enterprise level revenue is presented net of intercompany transaction eliminations.
(3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million, and Biopharma Laboratory Services revenue of $3,098 million.
(4) 2026 Updated Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.
Use of Adjusted Measures
The company has provided in this press release and accompanying tables "adjusted" financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company's operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company's financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise "special items" used for certain adjusted financial information are included in the tables accompanying this press release.
The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.
A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the "Events" section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company's former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company's information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
- End of Text -
- Tables to Follow -
LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Millions, Except Per Share Data)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenues
$ 3,731.1
$ 3,527.3
$ 7,268.7
$ 6,872.4
Cost of revenues
2,619.1
2,481.1
5,142.9
4,878.2
Gross profit
1,112.0
1,046.2
2,125.8
1,994.2
Selling, general, and administrative expenses
577.2
579.3
1,128.2
1,125.3
Amortization of intangibles and other assets
78.1
68.3
153.7
137.9
Restructuring and other charges
5.1
4.1
11.5
10.5
Operating income
451.6
394.5
832.4
720.5
Other (expense) income:
Interest expense
(61.1)
(57.1)
(116.2)
(113.1)
Investment income
5.6
1.7
17.8
8.2
Equity method loss, net
(6.2)
(1.7)
(11.3)
(2.0)
Other, net
(3.5)
(32.7)
(16.6)
(33.7)
Earnings from operations before income taxes
386.4
304.7
706.1
579.9
Provision for income taxes
87.3
66.4
129.0
128.6
Net earnings
299.1
238.3
577.1
451.3
Less: Net earnings attributable to the noncontrolling
interest
(0.4)
(0.4)
(0.6)
(0.6)
Net earnings attributable to Labcorp Holdings Inc.
$ 298.7
$ 237.9
$ 576.5
$ 450.7
Earnings per common share:
Basic earnings per common share
$ 3.66
$ 2.85
$ 7.03
$ 5.40
Diluted earnings per common share
$ 3.64
$ 2.84
$ 6.99
$ 5.36
Weighted-average basic common shares outstanding
81.7
83.4
82.0
83.5
Weighted-average diluted common shares outstanding
82.0
83.9
82.4
84.1
LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In Millions)
June 30, 2026
December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents
$ 141.8
$ 532.3
Accounts receivable, net
2,342.4
2,103.8
Unbilled services, net
162.4
156.9
Supplies inventory
562.2
534.7
Prepaid expenses and other
606.1
692.8
Total current assets
3,814.9
4,020.5
Property, plant, and equipment, net
3,100.5
3,081.5
Goodwill, net
7,030.1
6,789.5
Intangible assets, net
3,678.2
3,596.0
Joint venture partnerships and equity method investments
139.3
153.9
Other assets, net
769.3
751.3
Total assets
$ 18,532.3
$ 18,392.7
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable
$ 688.5
$ 840.8
Accrued expenses and other
862.4
847.8
Unearned revenue
387.8
439.1
Short-term operating lease liabilities
180.3
191.1
Short-term finance lease liabilities
4.7
4.6
Short-term borrowings and current portion of long-term debt
0.9
500.1
Total current liabilities
2,124.6
2,823.5
Long-term debt
5,857.6
5,084.6
Operating lease liabilities
661.0
682.6
Finance lease liabilities
61.6
63.0
Deferred income taxes and other tax liabilities
486.7
454.5
Other liabilities
717.6
647.8
Total liabilities
9,909.1
9,756.0
Commitments and contingent liabilities
Noncontrolling interest
16.4
16.9
Shareholders' equity:
Common stock, 80.9 and 82.2 shares outstanding at June 30, 2026, and
December 31, 2025, respectively
7.3
7.5
Additional paid-in capital
—
—
Retained earnings
8,701.4
8,639.9
Accumulated other comprehensive loss
(101.9)
(27.6)
Total shareholders' equity
8,606.8
8,619.8
Total liabilities and shareholders' equity
$ 18,532.3
$ 18,392.7
LABCORP HOLDINGS INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Millions)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings
$ 299.1
$ 238.3
$ 577.1
$ 451.3
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization
179.0
170.3
352.3
337.1
Stock compensation
34.9
34.1
66.6
66.9
Operating lease right-of-use asset expense
49.1
50.8
97.1
99.4
Deferred income taxes
24.4
(6.1)
26.4
(12.2)
Other, net
14.2
38.0
25.6
46.1
Change in assets and liabilities (net of effects of acquisitions and divestitures):
(Increase) decrease in accounts receivable
(59.2)
30.9
(247.1)
(139.9)
(Increase) decrease in unbilled services
(0.7)
0.9
(6.9)
4.8
Increase in supplies inventory
(65.1)
(11.9)
(29.7)
(3.5)
Decrease in prepaid expenses and other
23.1
12.8
27.1
57.8
(Decrease) increase in accounts payable
(11.7)
67.0
(150.4)
(80.6)
(Decrease) increase in unearned revenue
(17.6)
0.2
(49.7)
(8.7)
Decrease in accrued expenses and other
(24.0)
(4.7)
(51.4)
(179.4)
Net cash provided by operating activities
445.5
620.6
637.0
639.1
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures
(131.6)
(77.9)
(252.6)
(203.9)
Proceeds from sale of assets
1.9
1.9
9.7
2.4
Proceeds from sale or distribution of equity affiliates or other investments
—
6.9
—
6.9
Purchase of equity affiliates or other investments
(10.8)
(15.0)
(17.5)
(172.0)
Acquisition of businesses, net of cash acquired
(225.7)
(10.0)
(427.9)
(63.5)
Net cash used for investing activities
(366.2)
(94.1)
(688.3)
(430.1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from term loan
—
—
750.0
—
Payments on senior notes
(500.0)
—
(500.0)
(1,000.0)
Proceeds from accounts receivable securitization
175.0
—
175.0
225.0
Payments on accounts receivable securitization
(150.0)
—
(150.0)
—
Proceeds from revolving credit facilities
—
—
—
64.8
Payments on revolving credit facilities
—
—
—
(64.8)
Net share settlement tax payments from issuance of stock to employees
(6.3)
(3.5)
(46.1)
(29.0)
Net proceeds from issuance of stock to employees
1.8
—
34.7
25.7
Dividends paid
(58.7)
(59.9)
(119.9)
(121.5)
Purchase of common stock
(353.8)
(200.0)
(451.8)
(200.0)
Other, net
(27.9)
(4.0)
(31.3)
(7.3)
Net cash used for financing activities
(919.9)
(267.4)
(339.4)
(1,107.1)
Effect of exchange rate on changes in Cash and cash equivalents
1.3
18.8
0.2
26.7
Net (decrease) increase in Cash and cash equivalents
(839.3)
277.9
(390.5)
(871.4)
Cash and cash equivalents at beginning of period
981.1
369.4
532.3
1,518.7
Cash and cash equivalents at end of period
$ 141.8
$ 647.3
$ 141.8
$ 647.3
LABCORP HOLDINGS INC. AND SUBSIDIARIES
Condensed Combined Non-GAAP Segment Information
(Dollars in Millions)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Diagnostics Laboratories
Revenues
$ 2,900.7
$ 2,748.8
$ 5,662.8
$ 5,378.4
Adjusted operating income
$ 522.6
$ 482.8
$ 981.3
$ 910.3
Adjusted operating margin
18.0 %
17.6 %
17.3 %
16.9 %
Biopharma Laboratory Services
Revenues
$ 836.2
$ 784.8
$ 1,616.8
$ 1,506.1
Adjusted operating income
$ 142.2
$ 123.3
$ 262.9
$ 230.2
Adjusted operating margin
17.0 %
15.7 %
16.3 %
15.3 %
Consolidated
Revenues
$ 3,731.1
$ 3,527.3
$ 7,268.7
$ 6,872.4
Adjusted segment operating income
$ 664.8
$ 606.1
$ 1,244.2
$ 1,140.5
Unallocated corporate expense
(76.1)
(74.5)
(147.6)
(139.9)
Consolidated adjusted operating income
$ 588.7
$ 531.6
$ 1,096.6
$ 1,000.6
Adjusted operating margin
15.8 %
15.1 %
15.1 %
14.6 %
The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.
LABCORP HOLDINGS INC. AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
(Dollars and Shares in Millions, Except Per Share Data)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Adjusted Operating Income
Operating income
$ 451.6
$ 394.5
$ 832.4
$ 720.5
Amortization of intangibles and other assets (a)
78.1
68.3
153.7
137.9
Restructuring and other charges (b)
5.1
4.1
11.5
10.5
Acquisition and disposition-related costs (c)
21.3
15.1
31.2
44.2
LaunchPad costs (d)
11.7
17.2
24.7
37.3
Other
20.9
31.9
43.1
46.4
TSA reimbursement (e)
—
0.5
—
3.8
Adjusted operating income
$ 588.7
$ 531.6
$ 1,096.6
$ 1,000.6
Adjusted operating profit margin
15.8 %
15.1 %
15.1 %
14.6 %
Adjusted Net Income
Net income
$ 298.7
$ 237.9
$ 576.5
$ 450.7
Impact of adjustments to operating income
137.1
137.1
264.2
280.1
Loss on venture fund investments, net (f)
1.5
32.7
8.6
36.1
Equity method loss from SYNLAB investment (g)
6.2
—
11.2
—
TSA reimbursement (e)
—
(0.5)
—
(3.8)
Other
0.6
0.7
(7.9)
0.7
Income tax impact of adjustments (h)
(34.9)
(43.4)
(91.0)
(75.3)
Adjusted net income
$ 409.2
$ 364.5
$ 761.6
$ 688.5
Weighted-average diluted common shares outstanding
82.0
83.9
82.4
84.1
Adjusted net income per share
$ 4.99
$ 4.35
$ 9.24
$ 8.19
(a)
Amortization of intangible assets acquired as part of business acquisitions.
(b)
Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.
(c)
Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, and other integration or disposition related activities.
(d)
LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.
(e)
Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income.
(f)
The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.
(g)
Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.
(h)
Income tax impact of adjustments calculated based on the tax rate applicable to each item.
Labcorp spouští Marker by Labcorp™ Genetic Health Panel, který analyzuje 163 genů spojených s více než 100 lékařsky využitelnými dědičnými riziky. Test bude dostupný přes Labcorp OnDemand od 3. srpna 2026.
New offering analyzes 163 genes linked to more than 100 medically actionable conditions Includes genetic counseling support to help consumers understand results and take informed next steps Consumers can now access biomarker and hereditary genetic testing from a single source through Labcorp OnDemand , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of Marker by Labcorp™ Genetic Health Panel, a new offering designed to help consumers better understand inherited risks associated with more than 100 medically actionable health conditions. Available through Labcorp OnDemand, the panel analyzes 163 genes associated with hereditary cancer, cardiovascular conditions and metabolic conditions and includes access to licensed genetic counselors to help consumers understand their results and discuss appropriate next steps. The Marker by Labcorp Genetic Health Panel is backed by Labcorp's established expertise in clinical genetic testing through Labcorp Genetics and its Invitae genetic testing capabilities.
Photo courtesy of Labcorp Bridging Consumer Access and Clinical Genetics
Many people carry inherited genetic variants without knowing it. Research shows nearly one in six adults who undergo genetic testing discover a variant linked to a serious and medically actionable health condition. Family health history can provide important clues about inherited risk, but many people have incomplete or unavailable information about their relatives' health.
The Marker by Labcorp Genetic Health Panel was developed to help address this gap by combining clinical genetic testing, specimen collection and genetic counseling into a single consumer healthcare experience.
"Genetic information can play an important role in identifying health risks before symptoms appear, yet millions of people are unaware they carry an inherited genetic variant associated with an increased risk of serious disease," said Dr. Leslie Saltzman, vice president of consumer health solutions at Labcorp. "The Marker by Labcorp Genetic Health Panel expands access to genetic health insights by combining genetic testing, genetic counseling support and Labcorp's genetics expertise into a single, convenient healthcare experience. Consumers can now access both biomarker and genetic testing through Labcorp OnDemand from a single source, supporting a more comprehensive approach to understanding their health."
How the Testing Process Works
Consumers can purchase the Marker by Labcorp Genetic Health Panel directly through Labcorp OnDemand and schedule a blood draw at one of Labcorp's more than 2,200 patient service centers nationwide. Specimen collection is performed by a trained phlebotomist, after which samples are sent to Labcorp laboratories for analysis.
Results are delivered through Labcorp's secure patient portal and MyLabcorp™, the company's AI-powered mobile platform, where consumers can view their genetic health report alongside other available Labcorp test results. A comprehensive report includes any identified findings, educational resources tailored to individual results, and access to a licensed genetic counselor who can help interpret results, answer questions and discuss appropriate next steps.i Consumers may also share their results with healthcare providers to support further discussions or decisions about their care.
Marker by Labcorp expands the testing options available through Labcorp OnDemand, connecting consumers to both biomarker and hereditary genetic testing through a single trusted source.
The Marker by Labcorp Genetic Health Panel will be available through Labcorp OnDemand beginning August 3, 2026. To learn more, visit https://www.ondemand.labcorp.com/.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
i Results are not diagnostic and should be considered together with a person's medical history, family history and other risk factors.
Labcorp čeká ve 2. čtvrtletí růst tržeb o 5,4 % na 3,72 miliardy USD a růst EPS o 10,1 % na 4,79 USD. Tahounem mají být diagnostika, specializované testy a partnerství.
Key Takeaways Labcorp is expected to post Q2 revenue growth of 5.4% and EPS growth of 10.1% year over year.LH expanded diagnostics through partnerships, acquisitions and new oncology, neurology and consumer tests.Labcorp likely saw BLS support from Central Laboratories as Early Development streamlining continued. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its second-quarter 2026 results on July 30, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.25, surpassing the Zacks Consensus Estimate by 3.91%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.31%.
Q2 Estimates for LHThe Zacks Consensus Estimate for Labcorp’s second-quarter 2026 revenues is pegged at $3.72 billion. This suggests a 5.4% rise from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter EPS indicates an improvement of 10.1% to $4.79. The estimate has remained unchanged in the past 60 days.
Here's a quick review of the company’s performance leading up to its second-quarter earnings.
What Could Shape Labcorp's Q2 Results?In the second quarter of 2026, Diagnostics Laboratories’ (Dx) performance is likely to have continued to witness strong organic contribution. Labcorp's ongoing expansion through health system partnerships and acquisitions is expected to have supported testing volumes by broadening its patient and provider network. During the quarter, the company announced a nationwide strategic collaboration with Children's Hospital of Philadelphia to expand access to advanced diagnostics for pediatric patients.
In May, Labcorp launched an expanded DPYD Genotyping test to identify cancer patients at risk for severe chemotherapy side effects. Earlier in March, it acquired the select assets of Crouse Health's Laboratory Alliance of Central New York and executed an agreement to manage Crouse Health’s inpatient laboratories. All these developments are expected to have favorably boosted the quarter’s top line.
The company’s expanding specialty testing portfolio likely remained another tailwind. These tests are focused in the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market. In second-quarter 2026, Oncology results are likely to have benefited from the launch of several liquid biopsy tests and expanded access to molecular residual disease (MRD) solutions.
Labcorp further strengthened the portfolio by launching Agilent Technologies' FDA-approved companion diagnostic to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA. The company’s market-leading Alzheimer's testing portfolio may have boosted Neurology revenues.
Beyond the core testing, the company also introduced the first FDA-cleared rapid fentanyl test of its kind made in the United States, delivering results in just 10 minutes. The Labcorp OnDemand platform is also expected to have favorably supported revenues, driven by strong demand across its expanding menu of consumer health tests.
Labcorp may have also benefited from its ongoing use of advanced technologies, including AI and robotics, to enhance customer experiences and productivity. In April, the company expanded its collaboration with Epic, making its full test menu available through the Aura platform. Other recent initiatives include the development of an AI-powered real-world data platform with Amazon Web Services and Datavant to accelerate Alzheimer's research and a strategic collaboration with Optum.ai to streamline laboratory operations. Collectively, all these factors are expected to have positively impacted Labcorp’s second-quarter revenues.
The Zacks Consensus Estimate expects Dx revenues to grow 6.1% year over year.
Within the Biopharma Laboratory Services (“BLS”) segment,Labcorp has likely benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth.
The Zacks Consensus Estimate suggests that BLS revenues will grow 2.7% year over year.
Earnings Whispers for LabcorpPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of +0.71%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Key MedTech PicksHere are some other medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:
CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 5.
CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.79%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 3.3% from the year-ago quarter’s figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.
ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2026, to stockholders of record as of the close of business on August 28, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Key Takeaways Labcorp is expanding oncology, neurology and genetic testing to support long-term growth.LH's Q1 2026 revenues increased 5.8%, aided by acquisitions, partnerships and network expansion.Labcorp's AI, automation and launchpad savings initiatives aim to improve efficiency and margins. Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is well-poised for growth in the coming quarters owing to its progress on its strategic priority to lead in important specialty testing areas, which are growth drivers for both its businesses. Strategic partnerships and acquisitions help the company broaden its patient and provider network while deepening its presence in key markets. Additionally, it leverages AI and technology to enhance margins and customer experience. Yet, macroeconomic pressures and adverse currency swings pose risks for Labcorp.
In the past year, this Zacks Rank #2 (Buy) stock has risen 3.2% compared with 2.2% growth of the industry and a 23.3% increase of the S&P 500 Composite.
The renowned healthcare diagnostics company has a market capitalization of $21.20 billion. Labcorp’s earnings yield of 6.9% is well ahead of the industry’s 4.3% yield. In the trailing four quarters, the company delivered an average earnings surprise of 3.31%.
Let’s delve deeper.
Tailwinds Supporting LH StockTargeted Development in High-Growth Areas: Labcorp’s continued expansion in faster-growing specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, is strengthening its growth profile. In the first quarter of 2026, Neurology delivered double-digit growth, driven by an expanded Alzheimer's testing portfolio. Oncology benefited from several newly launched liquid biopsy tests and wider availability of MRD solutions. The MRD portfolio includes the Plasma Detect ID for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, as well as the Labcorp Plasma Detect Genome for stage III colon cancer, which is now available nationwide.
Image Source: Zacks Investment Research
The integration of Invitae has further expanded the company’s reach in genetic testing solutions. Labcorp is also collaborating with Illumina to advance precision oncology through applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. The Labcorp OnDemand consumer health platform delivered double-digit growth in the first quarter, supported by its expanded offerings.
Strategic Acquisitions and Partnerships to Drive Growth: In recent years, Labcorp has built a significant number of strategic relationships with health systems and regional/local laboratories, expanding its patient and provider network, and strengthening its presence in key markets. In the first quarter of 2026, enterprise revenues grew 5.8% year over year, with net acquisitions contributing 1.4%.
Recent activities include the purchase of select assets of Crouse Health’s Laboratory Alliance of Central New York’s (Lab Alliance) laboratory business and an agreement to manage their daily inpatient lab operations. Labcorp also acquired select assets of New York-based Empire City Laboratories, became the first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution, and signed a new multi-year partnership agreement with SOMOS.
Focus on Operational Efficiency: The company continues to benefit from its launchpad initiatives, which target $100-$125 million in savings annually. In the first quarter of 2026, Labcorp expanded its collaboration with PathAI to deploy an FDA-cleared digital pathology platform across its national anatomic pathology labs and hospital lab partnerships. Together with Amazon Web Services and Datavant, the company is developing a new AI-powered real-world data platform to accelerate Alzheimer's research. More recently, Labcorp teamed up with Optum.ai to simplify laboratory operations by advancing AI.
Across its core operations, AI and automation are already deployed in areas such as pathology, cytology and microbiology. Labcorp’s generative AI tool, Test Finder, is designed to simplify lab test selection and is also integrated into Labcorp Diagnostic Assistant.
What Ails Labcorp?Macroeconomic Risks: Labcorp’s operations are heavily dependent on the demand for diagnostic testing and drug development services from patients, physicians, hospitals, medical device companies, and others. In recent times, volatilities in global economic conditions, including inflation, have significantly reduced the demand for these services, affecting the customers’ ability to pay and, consequently, the profitability of the company. Added to this, the escalation of the present geopolitical tensions and retaliatory tariffs is putting pressure on the supply chain and services, increasing the prices of offerings. In the first quarter of 2026, the cost of revenues went up 5.3% year over year.
Exposed to Currency Headwind: Labcorp's huge exposure in international markets makes it vulnerable to currency fluctuations. With the recent upward trend observed in the value of the U.S. dollar, further acceleration expected by analysts in this value will cause the company’s revenues to face a tough situation overseas.
LH Stock’s Estimate TrendThe Zacks Consensus Estimate for Labcorp’s 2026 earnings per share (EPS) has increased 1 cent to $18.00 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $14.71 billion, implying 5.4% growth compared to the last year.
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared with the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 39.2% against the industry’s 7.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 9% against the industry’s 6.9% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 45.5% against the industry’s 7.4% decline over the past year.
Labcorp v USA spustila test ColoSense, jediný RNA-based domácí test schválený FDA pro screening kolorektálního karcinomu. Je dostupný po celé zemi a hradí se pro oprávněné příjemce Medicare a Medicare Advantage.
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) , /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA). Offered through a commercial collaboration with test developer Geneoscopy, ColoSense expands Labcorp's comprehensive portfolio of colorectal cancer screening solutions. The test is now covered for eligible Medicare and Medicare Advantage beneficiariesi following the Centers for Medicare & Medicaid Services (CMS) update to the National Coverage Determination (NCD) in June, with additional commercial coverage also available.
Photo courtesy of Labcorp Reducing Barriers to At-Home Screening
Colorectal cancer is highly preventable when detected early, yet approximately 4 in 10 eligible adults are not up to date with recommended screenings. While at-home tests offer convenience, the collection process can be a significant barrier to completion. According to Labcorp research, among users of at-home screening tests, 41% were uncomfortable preparing the sample, and 34% said the process felt messy. ColoSense is designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling.
"Labcorp is focused on improving colorectal cancer screening rates by offering at-home options consumers are more likely to complete," said Dr. Brian Caveney, chief medical and scientific officer at Labcorp. "With ColoSense now available nationwide, we're expanding access to an FDA-approved screening option that delivers advanced science and a more streamlined, easier-to-use collection experience."
Breakthrough Innovation Recognized by the FDA and Leading Cancer Authorities
ColoSense uses RNA-based technology to detect biomarkers associated with both colorectal cancer and advanced adenomas, precancerous changes that may be an early indication of disease. ColoSense received Breakthrough Device Designation from the FDA, which is reserved for medical devices that offer the potential for more effective diagnosis or treatment of life-threatening conditions. ColoSense aligns with stool-based RNA screening approaches recognized in the American Cancer Society (ACS) colorectal cancer screening guidelines and is included as a recommended screening option in the National Comprehensive Cancer Network (NCCN) guidelines.
"ColoSense reflects years of scientific innovation focused on improving how we screen for colorectal cancer at home," said Matt Sargent, chief commercial officer at Geneoscopy. "We're proud to partner with Labcorp to help bring this test into routine care nationwide and ensure more patients can benefit from earlier detection."
ColoSense is available through healthcare providers for adults aged 45 to 85 at average risk and is not for individuals with a history of colorectal cancer or certain high-risk conditions. ColoSense has demonstrated strong clinical performance, with 93% sensitivity for colorectal cancer in average-risk individuals, and achieved 100% sensitivityii for stage I colorectal cancer, detecting disease at its most treatable stage.
Once ordered, the collection kit is delivered directly to the consumer's home for collection and return, featuring a simplified design that eliminates the need to separate or mix the stool sample. Geneoscopy offers patient navigation support to help individuals understand their results and follow recommended next steps, including colonoscopy after a positive result. ColoSense is a screening test and does not replace diagnostic colonoscopy.
The introduction of ColoSense further expands Labcorp's portfolio of colorectal cancer screening options, providing patients and providers with greater choice and flexibility. To learn more, visit https://www.labcorp.com/treatment-areas/colorectal-cancer/crc-screening/colosense.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
About Geneoscopy, Inc.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other GI disease areas. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits, and availability from Labcorp, of the ColoSense screening test for colorectal cancer.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
iPatient Criteria: Age 45 to 85 years; asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test (gFOBT) or fecal immunochemical test (FIT)); and at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).
